A Review Of The Latest Xarelto Bleeding Lawsuit Information Surrounding MDL No. 2592 In Louisiana

February 22, 2016 – – BloodThinnerHelp.com reports on the latest details concerning anticoagulant drug Xarelto and the mounting lawsuit numbers it has become the subject of. Xarelto was released to consumers for use after a 2011 approval by the U.S. Food and Drug Administration. During its initial release, the new generation blood thinner was extremely popular. It did not require special diets and regular dosage adjustments or monitoring by physicians as other blood thinners had. Today, the drug is often used to prevent strokes for patients with atrial fibrillation condition, to treat pulmonary embolism and deep vein thrombosis, and to prevent blood clots among patients who are recovering from hip and knee replacement surgeries.

Xarelto has become, however, the topic of many lawsuits and much controversy. Today, lawsuits surrounding the drug number over 3,000: 2,800 of these have been consolidated to form MDL No. 2592 in Louisiana by the U.S. Judicial Panel for Multidistrict Litigation, while over 550 others have been consolidated by the Court of Common Pleas to form a mass tort litigation group in Philadelphia, Pennsylvania.

The FDA has since given Xarelto two black box warnings, which are the most strict warnings a product can receive before being completely recalled from the market. The warnings indicate an increased risk of blood clot formation among patients who suddenly stop using the drug without slowly weaning off of it and onto another anticoagulant. In other recent studies, patients switching from traditional blood thinners to Xarelto were shown to be at increased risk for stomach and eye bleeds, even when transitioning slowly and correctly.

Xarelto lawsuits have been filed against the drug’s manufacturers: Bayer AG and Janssen Pharmaceuticals. Janssen is a subdivision of well-known corporate giant Johnson & Johnson. Federally-filed lawsuits which have been consolidated in the Eastern District of Louisiana were filed by plaintiffs who all commonly allege that Xarelto puts those taking it at increased risk for serious and sudden bleeding events. They allege that the manufacturers used misleading marketing tactics to conceal these risks and force the public to focus on the positive aspects of the new drug.

The Honorable Judge Eldon Fallon, who is overseeing Xarelto cases involved in the MDL, has noted that four bellwether trials will be held in February of 2017 regarding the drug. Preparations for these bellwether trials took place in December of 2015 and January of 2016, and further trial preparations will be discussed in regular monthly status conferences. The next status conference will take place at the end of February, 2016.

As the cases get steadily closer to trial, Attorney Joseph Osborne is working to help ensure that those who feel they have been negatively affected by the drug will be given the important opportunity to explore their legal options in full. These patients may be entitled to substantial compensation to help with medical bills as well as pain and suffering. At this time, Attorney Osborne is offering complimentary legal consultations for affected individuals who are looking to seek justice.

To request further information regarding Xarelto bleeding lawsuits, or to ask questions, contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008282